Read by QxMD icon Read


Ethan Leng, Benjamin Spilseth, Lin Zhang, Jin Jin, Joseph S Koopmeiners, Gregory J Metzger
PURPOSE: Computer-aided detection/diagnosis (CAD) of prostate cancer (PCa) on multipara-metric MRI (mpMRI) is an active area of research. In the literature, the performance of predictive models trained to detect PCa on mpMRI has typically been reported in terms of voxel-wise mea-sures such as sensitivity and specificity and/or area under the receiver operating curve (AUC).However, it is unclear whether models that score higher by these measures are actually superior.Here, we propose a novel method for lesion identification as well as novel measures that assess the quality of the detected lesions...
March 15, 2018: Medical Physics
Sunao Shoji, Akio Hashimoto, Tomoya Nakamura, Shinichiro Hiraiwa, Haruhiro Sato, Yoshinobu Sato, Takuma Tajiri, Akira Miyajima
The present study evaluated three-dimensional shear wave elastography (3D SWE) in the detection of clinically significant prostate cancer. Clinically significant prostate cancer was defined by a minimum of one biopsy core with a Gleason score of 3+4 or 6 with a maximum cancer core length >4 mm. Patients with serum prostate-specific antigen levels of 4.0-20.0 ng/ml who were suspected of having prostate cancer from multi-parametric magnetic resonance imaging (mpMRI) were prospectively recruited. The 3D SWE was performed pre-biopsy, after which patients underwent MRI-transrectal ultrasound image-guided targeted biopsies for cancer-suspicious lesions and 12-core systematic biopsies...
April 2018: Biomedical Reports
Juan Gómez Rivas, Francesco Giganti, Mario Álvarez-Maestro, María Jose Freire, Veeru Kasivisvanathan, Luis Martinez-Piñero, Mark Emberton
CONTEXT: The indeterminate multiparametric prostate magnetic resonance image (mpMRI) lesion is one which cannot be classified as "positive" or "negative" for suspected cancer. Currently, there is no consensus on how to manage patients with indeterminate mpMRIs where areas cannot be classified as positives or negatives (Prostate Imaging Reporting and Data System [PI-RADS] 3 or Likert 3). OBJECTIVE: To define the concept of indeterminate lesion and describe the management strategies that may be adopted for these patients...
March 7, 2018: European Urology Focus
Amirali Salmasi, Jonathan Said, Alan W Shindel, Pooria Khoshnoodi, Ely R Felker, Anthony E Sisk, Tristan Grogan, Debbie McCullough, John Bennett, Helen Bailey, H Jeffrey Lawrence, David A Elashoff, Leonard S Marks, Steven S Raman, Phillip G Febbo, Robert E Reiter
PURPOSE: Multiparametric MRI (mpMRI) and biopsy-based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ (GPS) assay are increasingly used to improve risk stratification in men with clinically localized prostate cancer (PCa). The GPS assay was previously shown to be a significant independent predictor of adverse pathology (AP) at radical prostatectomy (RP) in men diagnosed with systematic biopsies only. We therefore investigated the ability of GPS to predict AP in the setting of MRI-guided prostate biopsy...
March 7, 2018: Journal of Urology
Hüseyin Cihan Demirel, John Warren Davis
Multiparametric magnetic resonance imaging (mpMRI) has managed to change the paradigms on prostate cancer detection and risk classification. The most clear-cut indication of mpMRI in guidelines is the patients with a history of negative biopsy/increasing prostate-specific antigen (PSA), and presence of additional findings supporting its use in non biopsied patients and active surveillance. mpMRI complements standard clinical exam, PSA measurements, and systematic biopsy, and will miss some tumors that lack enough size or change in tissue density...
March 2018: Turkish Journal of Urology
Stig Müller, Gunder Lilleaasen, Tor Erik Sand, Lars Løfsgaard, Manuela Estop-Garanto, Dan Helgø, Peter Sund, Vegard Mygland
PURPOSE: Since January 2015, all men referred to urologists in Norway due to elevated PSA or other suspicion of prostate cancer underwent multiparametric MRI (mpMRI) before prostate biopsy. At our hospital, patients and the initial MRI were assessed by an urologist and if deemed necessary, patients were referred to another institution for MR/US fusion biopsies. Before MR/US biopsy, patients underwent a second mpMRI. Since we noticed disagreement of these two mpMRIs before biopsy, we retrospectively assessed the level of agreement between the two mpMRIs from the two institutions...
March 5, 2018: World Journal of Urology
Sergio Righi, Martina Ugolini, Gianluca Bottoni, Matteo Puntoni, Massimiliano Iacozzi, Francesco Paparo, Manlio Cabria, Luca Ceriani, Monica Gambaro, Luca Giovanella, Arnoldo Piccardo
BACKGROUND: The aim of the present study is to evaluate the kinetics and dosimetry of64 CuCl2 in human prostate cancer (PCa) lesions. We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external beam radiation therapy. All patients underwent64 CuCl2 -PET/CT to detect PCa recurrence/metastases. Volumes of interest were manually drawn for each64 CuCl2 avid PCa lesion with a diameter > 1 cm on mpMRI in each patient. Time-activity curves for all lesions were obtained...
March 1, 2018: EJNMMI Research
Alison D Sheridan, Sameer K Nath, Sanjay Aneja, Jamil S Syed, Jay Pahade, Mahan Mathur, Preston Sprenkle, Jeffrey C Weinreb, Michael Spektor
OBJECTIVE: The purpose of this study was to determine imaging and clinical features associated with Prostate Imaging Reporting and Data System (PI-RADS) category 5 lesions identified prospectively at multiparametric MRI (mpMRI) that were found benign at MRI-ultrasound fusion targeted biopsy. MATERIALS AND METHODS: Between January 2015 and July 2016, 325 men underwent prostate mpMRI followed by MRI-ultrasound fusion targeted biopsy of 420 lesions prospectively identified and assessed with PI-RADS version 2...
February 28, 2018: AJR. American Journal of Roentgenology
Raj P Pal, Ros Ahmad, Shaun Trecartan, James Voss, Shaista Ahmed, Alvaro Bazo, Jon Lloyd, Thomas J Walton
OBJECTIVES: This study evaluated the diagnostic performance of Transrectal-ultrasound guided biopsy (TRUSB) and Multiparametric MRI (mpMRI) in detecting prostate cancer (CaP) against Transperineal prostate mapping biopsy (TPM) as the reference test. METHODS: Between April 2012 and January 2016 426 patients underwent TRUS biopsy, mpMRI and TPM. Patients initially underwent systematic 12 core TRUSB, followed 3 months later by mpMRI (1.5T, high resolution T2 images, DWI, DCE)...
February 22, 2018: Journal of Urology
Ashkan Mortezavi, Olivia Märzendorfer, Olivio F Donati, Gianluca Rizzi, Niels J Rupp, Marian S Wettstein, Oliver Gross, Tullio Sulser, Thomas Hermanns, Daniel Eberli
PURPOSE: To evaluate the diagnostic accuracy of mpMRI and mpMRI / transrectal ultrasound (TRUS) fusion-guided targeted biopsy (FTB) against transperineal template saturation prostate biopsy (TTSPB) for the detection of prostate cancer (PCa). PATIENTS AND METHODS: Retrospective analysis of 415 men consecutively presenting for prostate biopsy between 11/2014 and 9/2016 at our tertiary care centre. MpMRI (3-Tesla, without endorectal coil) was performed followed by TTSPB with the BiopSee® fusion system...
February 20, 2018: Journal of Urology
Kirsten Bouchelouche, Peter L Choyke
PURPOSE OF REVIEW: In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCa). This review highlights advances in PSMA PET in PCa during the past year. RECENT FINDINGS: PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCa, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI)...
February 19, 2018: Current Opinion in Oncology
Alexandre Fourcade, Charlotte Payrard, Valentin Tissot, Marie-Aimée Perrouin-Verbe, Nicolas Demany, Sophie Serey-Effeil, Pierre Callerot, Jean-Baptiste Coquet, Laurent Doucet, Charles Deruelle, Vincent Joulin, Michel Nonent, Georges Fournier, Antoine Valeri
OBJECTIVE: Compared with standard systematic transrectal ultrasound (TRUS)-guided biopsies (SBx), targeted biopsies (TBx) using magnetic resonance imaging (MRI)/TRUS fusion could increase the detection of clinically significant prostate cancer (PCa-s) and reduce non-significant PCa (PCa-ns). This study aimed to compare the performance of the two approaches. MATERIALS AND METHODS: A prospective, single-center study was conducted on all consecutive patients with PCa suspicion who underwent prebiopsy multiparametric MRI (mpMRI) using the Prostate Imaging Reporting and Data System (PI-RADS)...
February 20, 2018: Scandinavian Journal of Urology
Guilherme Moura Cunha, Cristiane A Villela-Nogueira, Anke Bergman, Flavia Paiva Proença Lobo Lopes
AIM: Multiparametric magnetic resonance imaging (mpMRI) may help determine the metabolic profile of patients with obesity and metabolic syndrome in addition to their clinical and laboratory biomarkers for diagnosis and monitoring. An abbreviated mpMRI protocol may be a faster, less-costly, and easier to perform alternative for the diagnosis, treatment, and follow-up of patients with NAFLD and for use in clinical trials. OBJECTIVE: To evaluate an abbreviated mpMRI protocol tailored to analyze quantitative imaging features of patients with obesity and NAFLD and assess its use during treatment...
February 15, 2018: Abdominal Radiology
David Thurtle, Tristan Barrett, Vineetha Thankappan-Nair, Brendan Koo, Anne Warren, Christof Kastner, Kasra Saeb-Parsy, Jenna Kimberley-Duffell, Vincent J Gnanapragasam
OBJECTIVE: To assess early outcomes since the introduction of an active surveillance (AS) protocol incorporating mpMRI guided baseline biopsies and image based surveillance. PATIENTS AND METHODS: A new AS protocol mandating image-guided baseline biopsies, annual mpMRI and 3 monthly PSA but which retained protocol re-biopsies was tested. Pathological progression, treatment conversion and triggers for non-protocol biopsy were recorded prospectively. RESULTS: Data from 157 men enrolled on this protocol (median: age 64years, PSA 6...
February 13, 2018: BJU International
Irene A Burger, Andrei Gafita, Julian Müller, Benedikt Kranzbühler, Olivio F Donati, Daniel Eberli
Restaging local recurrence after high-intensity focused ultra-sound (HIFU) is based on multiparametric MRI (mpMRI). However, postinterventional changes of the tissue, such as edema or hemorrhage, are limiting tumor detection on mpMRI. We present a case of a rising prostate-specific antigen values, negative mpMRI, and a Gleason score of 4+4 on template biopsy after HIFU. On F-choline PET/MR, high focal uptake was detected at the location of positive biopsy. Re-HIFU based on the fused F-choline PET/MR images was performed, followed by a recurrence-free period of 11 months...
April 2018: Clinical Nuclear Medicine
Sonia Gaur, Baris Turkbey
Prostate multiparametric MR imaging (mpMRI) plays an important role in local evaluation after treatment of prostate cancer. After radical prostatectomy, radiation therapy, and focal therapy, mpMRI can be used to visualize normal post-treatment changes and to diagnose locally recurrent disease. An understanding of the various treatments and expected changes is essential for complete and accurate post-treatment mpMRI interpretation.
March 2018: Radiologic Clinics of North America
Petar Duvnjak, Ariel A Schulman, Jamie N Holtz, Jiaoti Huang, Thomas J Polascik, Rajan T Gupta
Meaningful changes to the approach of prostate cancer staging and management have been made over the past decade with increasing demand for high-quality multiparametric MR imaging (mpMRI) of the prostate. This article focuses on the evolving paradigm of prostate cancer staging, with emphasis on the role of mpMRI on staging and its integration into clinical decision making. Current prostate cancer staging systems are defined and mpMRI's role in the detection of non-organ-confined disease and how it has an impact on the selection of appropriate next steps are discussed...
March 2018: Radiologic Clinics of North America
Egesta Lopci, Alberto Saita, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, Nicolò Maria Buffi, Rodolfo Hurle, Katia Marzo, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Pasquale Cardone, Angelo Castello, Davide Maffei, Luca Balzarini, Arturo Chiti, Giorgio Guazzoni, Paolo Casale
BACKGROUND: 68 Ga-PSMA PET/CT may represent the most promising imaging modality for identification and risk stratification of prostate cancer (PCa) in patients with contraindications to or negative multiparametric MRI (mpMRI). METHODS: This prospective observational study analyzed68 Ga-PSMA PET/CT in a selected group of patients with persistently elevated PSA and/or PHI (prostate health index) suspicious for PCa, negative digital rectal examination, and at least one negative biopsy...
January 31, 2018: Journal of Urology
Susan Prendeville, Mark Gertner, Manjula Maganti, Melania Pintilie, Nathan Perlis, Ants Toi, Andrew J Evans, Antonio Finelli, Theodorus H van der Kwast, Sangeet Ghai
PURPOSE: The aim of this study was to compare biopsy detection of intraductal (IDC) and cribriform (CR) pattern invasive prostate carcinoma (PCa) in mpMRI positive and negative regions of the prostate. MATERIAL AND METHODS: A prospectively maintained single institution database was queried to identify patients who underwent mpMRI/US fusion targeted biopsy (MRI-TBx) and concurrent systematic sextant biopsy of MRI negative regions (SMN-Bx) between January 2013 and May 2016...
January 31, 2018: Journal of Urology
Thenappan Chandrasekar, Hanan Goldberg, Zachary Klaassen, Nathan Perlis, Antonio Finelli, Andrew Evans, Sangeet Ghai
No abstract text is available yet for this article.
February 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"